&nbsp;

2016PSQISupplementaryTables.xlsx

Dec 1969

Guidelines and Advice

2019 Antiemetic Recommendations for Chemotherapy-Induced Nausea and Vomiting: A Clinical Practice Guideline

Status: Current
ID: GL-C50-09

Dec 1969

Regimen

XELOX

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Adjuvant

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

oxaliplatin,

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph, Patient Info Sheet (XELOX)

Nov 2023

Regimen

XELOX

Cancer Type:

Unknown Primary

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

oxaliplatin,

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph

Regimen

XELOX

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Adjuvant, Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

oxaliplatin,

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph

Document

2018 CSRT CoP Annual Report

Dec 1969

Document

2019_Ontario_Medical_Physics_Residency_Program_CAMPEP_Statistics_Final

Dec 1969

Document

XELOX.pdf

Dec 1969

Document

XELOX-FR.pdf

Dec 1969

Document

2018pebc_conflict_of_interest_policy_2018_May

Jul 2020

Regimen

XELOX+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Document